BioSpace News Archive

Aptinyx Inc. announced that company management will present at the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022.

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that Chief Executive Officer Nadav Kidron will present an in-person company overview at the H.C. Wainwright Global Investment Conference, on May 25, 2022 in Miami, Florida.

Aeterna Zentaris Inc. announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.

Baudax Bio, Inc., a pharmaceutical company focused on innovative products for acute care settings, announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the H.C. Wainwright Annual Global Life Sciences Conference, taking place in Miami, Florida on Wednesday, May 25, 2022, at 1:30 p.m. Eastern Time.

Gain Therapeutics, Inc. announced that the company’s Chief Executive Officer, Eric Richman, will present and host one-on-one meetings at the H.C. Wainwright Global Investment Conference taking place May 23-25 in Miami, Florida.

Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a clinical-stage company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that the first subject has been dosed in its three-part Phase 1 clinical trial.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune diseases, announced today the appointment of four new members to the Company’s Clinical Advisory Board (CAB).

iCAD, Inc. announced that new research supporting ProFound AI® for Digital Breast Tomosynthesis will be presented at the Society of Breast Imaging Breast Imaging Symposium, taking place May 16-19 in Savannah, GA.

Laekna Therapeutics (" Laekna "), a clinical-stage global biotechnology company dedicated to developing next generation medicines to treat cancer and liver diseases, announced that it has raised $61 million in Series D financing led by CS Capital with support from Worldstar, and Infinity Capital.

Alcyone Therapeutics Inc. (“Alcyone”), a biotechnology company pioneering next-generation precision gene-based therapies for complex neurological conditions, today presents preclinical data showing the Company’s partnered novel adeno associated virus serotype 9 (AAV9) gene therapy vector ACTX-101.